Scott C. Bell

A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation

Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney et al. · New England Journal of Medicine · 2011 · 2.1K citations · Full text

Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals

David J. Lederer, Scott C. Bell, Richard D. Branson et al. · Annals of the American Thoracic Society · 2018 · 697 citations · Full text

Quasi-experiment, Causal Inference, Critical Care Medicine +23

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium

Josephine M. Bryant, Dorothy Grogono, Daniela Rodriguez-Rincon et al. · Science · 2016 · 576 citations · Full text

Medical Microbiology, Antimicrobial Resistance Gene, Pathogenic Microbiology +13

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Michael Boyle, Scott C. Bell, Michael W. Konstan et al. · The Lancet Respiratory Medicine · 2014 · 436 citations

Pathology, Cftr Corrector, Pulmonary Fibrosis +3

Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease

Rajiv Khanna, Scott C. Bell, Martina A. Sherritt et al. · Proceedings of the National Academy of Sciences · 1999 · 330 citations